Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRELUDE: Neoadjuvant Lu-177-PSMA-617 in High Risk Localized Prostate Cancer
NCT06798558Phase 2Recruiting
- Sponsor
- Hackensack Meridian Health
- Start
- Mar 2025
- Primary completion
- Mar 2029
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium lu 177 vipivotide tetraxetan in prostate adenocarcinoma, sponsored by Hackensack Meridian Health. Started Mar 2025; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT06798558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06798558.